Results on Charm Baryon Spectroscopy from Tevatron

Due to an excellent mass resolution and a large amount of available data, the CDF experiment, located at the Tevatron proton-antiproton accelerator, allows the precise measurement of spectroscopic properties, like mass and decay width, of a variety of states. This was exploited to examine the first orbital excitations of the Lambda_c baryon, the resonances Lambda_c(2595) and Lambda_c(2625), in the decay channel Lambda_c^+ pi^+ pi^-, as well as the Lambda_c spin excitations Sigma_c(2455) and Sigma_c(2520) in its decays to Lambda_c^+ pi^- and Lambda_c^+ pi^+ final states in a data sample corresponding to an integrated luminosity of 5.2 invfb. We present measurements of the mass differences with respect to the Lambda_c and the decay widths of these states, using significantly higher statistics than previous experiments.Comment: submitted to Proceedings of the International Workshop on Charm Physics (Charm 2010

Hidden Charm Spectroscopy from Tevatron

The observation of a narrow structure near the J/{psi}{phi} threshold in exclusive B{sup +} {yields} J/{psi}{phi} K{sup +} decays produced in p{bar p} collisions at {radical}s = 1.96 TeV is reported. A signal of 19 {+-} 6(stat) {+-} 3(syst) events, with statistical significance of 5.0 standard deviations, is seen in a data sample corresponding to an integrated luminosity of 6.0 fb{sup -1}, collected by the CDF II detector. The mass and natural width of the structure are determined to be m = 4143.4{sub -3.0}{sup +2.9}(stat) {+-} 0.6(syst)MeV/c{sup 2} and {Lambda} = 15.3{sub -6.1}{sup +10.4}(stat) {+-} 2.5(syst)MeV/c{sup 2}, consistent with the previous measurements reported as evidence of the Y (4140)

Antagonism of the mammalian target of rapamycin selectively mediates metabolic effects of epidermal growth factor receptor inhibition and protects human malignant glioma cells from hypoxia-induced cell death

Although inhibition of the epidermal growth factor receptor is a plausible therapy for malignant gliomas that, in vitro, enhances apoptosis, the results of clinical trials have been disappointing. The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that integrates starvation signals and generates adaptive responses that aim at the maintenance of energy homeostasis. Antagonism of mTOR has been suggested as a strategy to augment the efficacy of epidermal growth factor receptor inhibition by interfering with deregulated signalling cascades downstream of Akt. Here we compared effects of antagonism of mTOR utilizing rapamycin or a small hairpin RNA-mediated gene silencing to those of epidermal growth factor receptor inhibition or combined inhibition of epidermal growth factor receptor and mTOR in human malignant glioma cells. In contrast to epidermal growth factor receptor inhibition, mTOR antagonism neither induced cell death nor enhanced apoptosis induced by CD95 ligand or chemotherapeutic drugs. However, mTOR inhibition mimicked the hypoxia-protective effects of epidermal growth factor receptor inhibition by maintaining adenosine triphosphate levels. These in vitro experiments thus challenge the current view of mTOR as a downstream target of Akt that mediates antiapoptotic stimuli. Under the conditions of the tumour microenvironment, metabolic effects of inhibition of epidermal growth factor receptor, Akt and mTOR may adversely affect outcome by protecting the hypoxic tumour cell fractio

Efficacy and toxicity of bimodal radiotherapy in WHO grade 2 meningiomas following subtotal resection with carbon ion boost:Prospective phase 2 MARCIE trial

Background: Novel radiotherapeutic modalities using carbon ions provide an increased relative biological effectiveness (RBE) compared to photons, delivering a higher biological dose while reducing radiation exposure for adjacent organs. This prospective phase 2 trial investigated bimodal radiotherapy using photons with carbon-ion (C12)-boost in patients with WHO grade 2 meningiomas following subtotal resection (Simpson grade 4 or 5).Methods:A total of 33 patients were enrolled from July 2012 until July 2020. The study treatment comprised a C12-boost (18 Gy [RBE] in 6 fractions) applied to the macroscopic tumor in combination with photon radiotherapy (50 Gy in 25 fractions). The primary endpoint was the 3-year progression-free survival (PFS), and the secondary endpoints included overall survival, safety and treatment toxicities. Results:With a median follow-up of 42 months, the 3-year estimates of PFS, local PFS and overall survival were 80.3%, 86.7%, and 89.8%, respectively. Radiation-induced contrast enhancement (RICE) was encountered in 45%, particularly in patients with periventricularly located meningiomas. Patients exhibiting RICE were mostly either asymptomatic (40%) or presented immediate neurological and radiological improvement (47%) after the administration of corticosteroids or bevacizumab in case of radiation necrosis (3/33). Treatment-associated complications occurred in 1 patient with radiation necrosis who died due to postoperative complications after resection of radiation necrosis. The study was prematurely terminated after recruiting 33 of the planned 40 patients. Conclusions:Our study demonstrates a bimodal approach utilizing photons with C12-boost may achieve a superior local PFS to conventional photon RT, but must be balanced against the potential risks of toxicities.</p

Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial

PURPOSE: The EORTC-26101 study was a randomized phase II and III clinical trial of bevacizumab in combination with lomustine versus lomustine alone in progressive glioblastoma. Other than for progression-free survival (PFS), there was no benefit from addition of bevacizumab for overall survival (OS). However, molecular data allow for the rare opportunity to assess prognostic biomarkers from primary surgery for their impact in progressive glioblastoma. EXPERIMENTAL DESIGN: We analyzed DNA methylation array data and panel sequencing from 170 genes of 380 tumor samples of the EORTC-26101 study. These patients were comparable with the overall study cohort in regard to baseline characteristics, study treatment, and survival.RESULTS: Of patients' samples, 295/380 (78%) were classified into one of the main glioblastoma groups, receptor tyrosine kinase (RTK)1, RTK2 and mesenchymal. There were 10 patients (2.6%) with isocitrate dehydrogenase mutant tumors in the biomarker cohort. Patients with RTK1 and RTK2 classified tumors had lower median OS compared with mesenchymal (7.6 vs. 9.2 vs. 10.5 months). O6-methylguanine DNA-methyltransferase (MGMT) promoter methylation was prognostic for PFS and OS. Neurofibromin (NF)1 mutations were predictive of response to bevacizumab treatment.CONCLUSIONS: Thorough molecular classification is important for brain tumor clinical trial inclusion and evaluation. MGMT promoter methylation and RTK1 classifier assignment were prognostic in progressive glioblastoma. NF1 mutation may be a predictive biomarker for bevacizumab treatment.</p

Modular und 3D-gedruckt

Der Hauptkostenträger bei der Herstellung von Kunststoffbauteilen im Spritzgussverfahren ist die Herstellung der Spritzgussform. Besonders bei komplexen Geometrien fallen hohe Kosten und Herstellzeiten für gefräste und erodierte Formen an. Aus diesem Grund können Investitionen in Spritzgussformen fast ausschliesslich mit hohen Stückzahlen begründet werden